CClinicalTrials.gg
CompletedNCT07416708Updated Mar 4, 2026

The Impact of Transcutaneous Vagal Nerve Stimulation on Frailty Syndrome in Older Adults

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation and Physiotherapy in Frailty Syndrome and Dementia, sponsored by Balnear and Rehabilitation Sanatorium Techirghiol. Completed at 1 site in Romania. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Balnear and Rehabilitation Sanatorium Techirghiol · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Dec 2024, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

This clinical study, conducted at the Techirghiol Balneary and Rehabilitation Sanatorium, aims to evaluate the effectiveness of transcutaneous auricular vagus nerve stimulation (taVNS) in improving clinical and biological parameters associated with frailty in older adults. Over a two-week period, participants aged over 60 years, without dementia, cardiac pacemakers, or auditory implants, will be assigned to two groups: an intervention group receiving active taVNS and a control group receiving sham stimulation. Both groups will undergo individualized medical rehabilitation therapies according to their clinical needs.

The study will assess frailty using the Edmonton Frailty Scale, sleep quality through the Pittsburgh Sleep Quality Index, and cognitive function with the Montreal Cognitive Assessment (MoCA) and the Rapid Cognitive Screen. Additionally, inflammatory markers (C-reactive protein, IL-6, TNF-alpha) will be measured at baseline and upon discharge.

The primary objective is to demonstrate that the intervention group will show greater improvements in cognitive scores, sleep quality, and reductions in inflammatory markers compared to the control group at the end of the study.

02

Conditions studied

  • Frailty Syndrome
  • Dementia
03

In context

Frailty

1,198 studies on the registry are indexed under Frailty; 429 are open to participants now.

This study's enrollment of 80 is close to the median of 80 across 680 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Balnear and Rehabilitation Sanatorium Techirghiol is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Age ≥ 60 years.

  • Vertebro-peripheral osteoarthritic disease without contraindication for physiotherapy
  • Patients with cognitive capacity to understand

Exclusion criteria

Exclusion Criteria:

  • History of major psychiatric disorders, under psychiatric medication or optimal treatment for associated symptoms.

    • Long-term use of corticosteroid or nonsteroidal anti-inflammatory drugs up to one month before the study
    • Sedative medication during hospitalization.
    • Allergies or sensitivities to electrodes or the Nurosym device.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Aurical Vagus Nerve Stimulated Patients

    The patients received 1h per day auricular vagus nerve stimulation and individual rehabilitation procedures

    Device: Transcutaneous Auricular Vagus Nerve Stimulation · Procedure: Physiotherapy

  • Sham comparator
    Sham Group - Non stimulated patients

    These patients only received individual rehabilitation procedures

    Procedure: Physiotherapy

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation

    All patients received individual rehabilitation procedures tailored on their musculoskeletal degenerative disease.

    Also known as: Phisiotherapy

  • ProcedurePhysiotherapy

    Physiotherapy is a non-invasive treatment used to relieve pain, improve mobility, and speed up recovery after injuries, surgeries, or chronic conditions. It helps restore body functions, improve posture, and prevent relapses.

06

What researchers measure

Primary outcomes

  1. Evaluation of the transcutaneous vagal nerve stimulation (Auricular Vagal Neuromodulation Therapy) on Cognitive Frailty

    Investigation of AVNT effect on cognitive frailty using the Montreal Cognitive Assessment (MoCA-B), Edmonton Frailty Scale, and Rapid Cognitive Screen Test (RCS). Every one of the test is measured in units of a scale. For Montreal Cognitive Assessment - Basic (MoCA-B) the total Score is 30 points. A score ≥ 26 is generally considered within normal limits Scores \< 26 may suggest mild cognitive impairment (MCI). \< 20 may suggest moderate cognitive impairment. In this study, we calculated both the total MoCA-B score and separate domain-specific scores to identify domain-level changes more precisely. The Rapid Cognitive Test is a brief screening instrument used to detect mild cognitive impairment and early dementia. Maximum score:10 ; ≤5: Suggestive of dementia For the Edmonton Frail Scale (EFS), the scoring system is: Total score range: 0-17; Higher scores indicate greater frailty. It was administered only at baseline (upon admission) as a reference measure of frailty status.

    Time frame: From enrollment to the end of treatment at 10 days - MOCA-B and RCS test The Edmonton Frailty Scale was only used at admission as a reference measure of frailty status because meaningful changes in frailty status typically require longer time intervals.

Secondary outcomes

  1. Effects of AVNT (Trans-auricular vagus nerve stimulation) therapy on sleep quality

    We used the Pittsburgh Sleep Quality Index (PSQI) to asses the quality of sleep. Scoring - units per scale Total score range: 0-21 Score ≤ 5: Good sleep quality Score \> 5: Poor sleep quality Higher scores indicate worse sleep quality. The PSQI evaluates 7 components: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbances, Use of sleep medication, Daytime dysfunction. In this study, both total PSQI score and component-level changes were analyzed.

    Time frame: We performed 2 measurements on day 1 and one on the final day (day 10)

Other outcomes

  1. The effects of AVNT (trans-auricular vagus nerve stimulation) therapy on inflammation

    We will assess quantitative C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). Reference Range and measurement unit 1. IL-6: Typically \< 7 pg/mL Values \> 7 pg/mL indicate elevated inflammatory activity 2. Tumor Necrosis Factor Alpha (TNF-α) Typically \< 8 pg/mL 3. Quantitative C-reactive protein (CRP) \< 5 mg/L: Normal 5-10 mg/L: Mild inflammation 10 mg/L: Significant inflammation (acute or chronic) 4\. Erythrocyte Sedimentation Rate (ESR) For men: \< 20 mm/hour For women: \< 30 mm/hour

    Time frame: We performed 2 measurements: on the 1 day and on the final day (day 10)

07

Study locations

1 site
  • Balneal and Rehabilitation Sanatorium Techirghiol
    Techirghiol, Constanța County 906100, Romania
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07416708
Lead sponsor
Balnear and Rehabilitation Sanatorium Techirghiol
Responsible party
Elena-Valentina Ionescu (Assit. Prof. Dr. Ionescu Elena Valentina, Balnear and Rehabilitation Sanatorium Techirghiol) — Principal investigator
First posted
Feb 18, 2026
Start date
Dec 1, 2024
Primary completion
May 1, 2025
Completion
May 15, 2025
Last update
Mar 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion